Banco Santander S.A. Raises Stock Position in IQVIA Holdings Inc. $IQV

Banco Santander S.A. increased its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 25.2% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 150,557 shares of the medical research company’s stock after purchasing an additional 30,331 shares during the period. Banco Santander S.A.’s holdings in IQVIA were worth $33,937,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the company. Claret Asset Management Corp lifted its holdings in IQVIA by 1.1% during the 3rd quarter. Claret Asset Management Corp now owns 4,527 shares of the medical research company’s stock valued at $860,000 after buying an additional 49 shares in the last quarter. Leonard Rickey Investment Advisors P.L.L.C. raised its holdings in shares of IQVIA by 3.3% in the 4th quarter. Leonard Rickey Investment Advisors P.L.L.C. now owns 1,814 shares of the medical research company’s stock valued at $409,000 after purchasing an additional 58 shares in the last quarter. Quadrant Capital Group LLC raised its holdings in shares of IQVIA by 1.3% in the 4th quarter. Quadrant Capital Group LLC now owns 4,792 shares of the medical research company’s stock valued at $1,080,000 after purchasing an additional 60 shares in the last quarter. Brookstone Capital Management raised its holdings in shares of IQVIA by 2.2% in the 4th quarter. Brookstone Capital Management now owns 2,931 shares of the medical research company’s stock valued at $661,000 after purchasing an additional 63 shares in the last quarter. Finally, Private Advisor Group LLC raised its holdings in shares of IQVIA by 1.0% in the 3rd quarter. Private Advisor Group LLC now owns 6,122 shares of the medical research company’s stock valued at $1,163,000 after purchasing an additional 63 shares in the last quarter. 89.62% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

IQV has been the subject of several recent analyst reports. Weiss Ratings lowered shares of IQVIA from a “hold (c)” rating to a “hold (c-)” rating in a research note on Monday, May 4th. Wall Street Zen downgraded shares of IQVIA from a “buy” rating to a “hold” rating in a research report on Saturday, June 6th. TD Cowen raised shares of IQVIA from a “hold” rating to a “buy” rating and boosted their target price for the stock from $174.00 to $213.00 in a research report on Monday, March 9th. Morgan Stanley set a $225.00 target price on shares of IQVIA in a research report on Thursday, May 7th. Finally, Barclays raised shares of IQVIA from an “equal weight” rating to an “overweight” rating and set a $210.00 target price on the stock in a research report on Friday, March 6th. Two analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, IQVIA currently has an average rating of “Buy” and a consensus price target of $224.13.

IQVIA Stock Up 0.0%

Shares of NYSE:IQV opened at $181.10 on Friday. The company has a market capitalization of $30.23 billion, a PE ratio of 22.44, a P/E/G ratio of 1.55 and a beta of 1.21. The company has a current ratio of 0.75, a quick ratio of 0.75 and a debt-to-equity ratio of 2.20. IQVIA Holdings Inc. has a twelve month low of $153.01 and a twelve month high of $247.04. The firm has a 50 day simple moving average of $173.56 and a 200-day simple moving average of $193.68.

IQVIA (NYSE:IQV) last announced its earnings results on Tuesday, May 5th. The medical research company reported $2.90 EPS for the quarter, beating analysts’ consensus estimates of $2.83 by $0.07. The business had revenue of $4.15 billion for the quarter, compared to analysts’ expectations of $4.10 billion. IQVIA had a net margin of 8.33% and a return on equity of 30.50%. The company’s quarterly revenue was up 8.4% on a year-over-year basis. During the same period in the previous year, the company posted $2.70 EPS. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. On average, equities analysts predict that IQVIA Holdings Inc. will post 11.6 EPS for the current fiscal year.

IQVIA declared that its board has authorized a share buyback program on Thursday, May 7th that authorizes the company to buyback $2.00 billion in outstanding shares. This buyback authorization authorizes the medical research company to purchase up to 6.8% of its shares through open market purchases. Shares buyback programs are often an indication that the company’s leadership believes its stock is undervalued.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.